On behalf of myself, I respectfully request the NCCN Lymphoma & Leukemia Guideline panels to review the enclosed data for consideration of Vitamin D-25OH and bone mineral density testing in these patient populations.

**Specific Changes:** Recommend the serum free light chain assays as a routine component of the initial diagnostic evaluation of multiple myeloma (changed from “useful under some circumstances”).

Add language in workup for NHL, HL, and CLL:

**Consider Vitamin D-25OH and bone mineral density testing.**

**Rationale:**

The following articles are submitted in support of this proposed change.

**Bone Mineral Density Testing**
(see also manuscript references for deeper background):

"...prevention of bone loss is better than reversal of bone loss, since bone loss is a multifactorial, dynamic & complicated process" [4/9/15] Oncology Times
http://journals.lww.com/oncology-times/blog/onlinefirst/Pages/post.aspx?PostID=1237


**Zoledronic Acid for Prevention of Bone Loss in Lymphoma** [2013] @Lymphoma_Doc @mtmdphd et al. CLML http://ow.ly/zENQp #lymsm #SuppOnc

**BMD screening should be routine in lymphoma** [2014] @mtmdphd @Lymphoma_Doc Hagemeister @Annals_Oncology http://ow.ly/zENbR #lymsm


Increased Fractures in Hematopoietic SCT Pts [2015] Pundole et al. #JCOResearch http://ow.ly/N5H3z #bmtsm #mmsm #lymsm #SuppOnc

Incr Incidence of Fractures in Recipients of Hematopoietic SCT. Multi-variate risks: myeloma, Auto, age http://ow.ly/KMEzl #bmtsm #mmsm
Vitamin D25OH testing in Hematologic Malignancies

Vitamin D assoc w/ survival in lymphoma patients [2009] Witzig @MayoCancerCare on @YouTube http://ow.ly/9Xbi302EF7X #lymsm #SuppOnc


Vitamin D insuff & prognosis in chronic lymphocytic leukemia (CLL) [2011] Shanafelt et al. @MayoLeukemiaMDS http://ow.ly/MQZO1 #leusm

Vit D Rec upregulation in alloreactive human T cells [2012] Joseph et al @drkomanduri Hum Immunol http://ow.ly/LxNhQ #ImmunoOnc #lymsm


Vit D Replacement Effect Tumor Response & Survival in Vit D Insuffic CA Pts @MayoCancerCare http://ow.ly/kJAb302FJOF #NCT01787409 #SuppOnc

Sincerely,

Michael A. Thompson, MD, PhD
Michael.A.Thompson@aurora.org

Medical Director, Early Phase Cancer Research Program
Medical Co-Director, Oncology Precision Medicine Program
Co-PI, Aurora NCI Community Oncology Research Program (NCORP)
Aurora Research Institute
Aurora Cancer Care
Aurora Health Care

Clinical Adjunct Assistant Professor
Department of Medicine
University of Wisconsin School of Medicine